TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6800465
Drug: 1850 APTT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1850 APTT units of low‐molecular‐weight heparin as a single injection
Study: 14726838
Drug: Low‐molecular‐weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low‐molecular‐weight heparin
Study: 6800465
Drug: Equal amounts
Normalized name: equol, (+-)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Equal amounts of low‐molecular‐weight heparin and unfractionated heparin
Study: 15767472
Drug: Cryotherapy treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cryotherapy treatment
Study: 28591280
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin type A (BTX‐A) injections into the orbicularis muscle
Study: 26602423
Drug: Fermented, protein-fortified
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fermented, protein-fortified dairy product (15 g protein/150 g)
Study: 26602423
Drug: Control (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (3 g protein/150 g)
Study: 24337761
Drug: Modafinil 200
Normalized name: modafinil 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modafinil 200 mg/day for 15 days
Study: 21855271
Drug: Proximal surface
Normalized name: hepatitis B surface antigen vaccine Injection [Recombivax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proximal surface treatment with hydroxyapatite coating
Study: 21855271
Drug: Proximal surface
Normalized name: hepatitis B surface antigen vaccine Injection [Recombivax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proximal surface treatment without hydroxyapatite coating
Study: 11235062
Drug: Natural progesterone
Normalized name: NATURAL PROGESTERONE CREAM,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natural progesterone creams
Study: 9683116
Drug: Geragogy-based medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Geragogy-based medication instruction
Study: 9683116
Drug: Usual preprinted
Normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual preprinted discharge instructions with handwritten medication information
Study: 27760062
Drug: Brief Intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brief Intervention (BI) and Cognitive Behavioral Therapy (CBT)
Study: 22489518
Drug: Spinal manipulation
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal manipulation treatment assisted with orthopedic footwear
Study: 22489518
Drug: Spinal manipulation
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal manipulation treatment only (Control)
Study: 7926297
Drug: Antibodies to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibodies to 37k antigen
Study: 7926297
Drug: Antibodies to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibodies to GAD
Study: 7926297
Drug: GAD antibody
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: GAD antibody levels
Study: 2574190
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg nizatidine every 8 hours
Study: 2574190
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg nizatidine every 12 hours
Study: 31242931
Drug: Transdermal GTN
Normalized name: GTN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal GTN (5 mg/day), administered as a transdermal patch by paramedics in the prehospital setting within 3 h of stroke onset and continued for 24 h
Study: 26522892
Drug: Subconjunctival injection
Normalized name: STREPTOMYCES GRISEUS 0.05 g in 1 mL SUBCONJUNCTIVAL INJECTION, SOLUTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subconjunctival injection of 10mg (0.4mL) of bevacizumab
Study: 26522892
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy with verteporfin (6mg/m²)
Study: 26522892
Drug: Combined treatment:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment: subconjunctival injection of bevacizumab followed by photodynamic therapy 7 days later
Study: 11284817
Drug: esmolol 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: esmolol 1.5 mg.kg‐1
Study: 6356756
Drug: Midazolam (0.13
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.13 mg/kg)
Study: 19319008
Drug: Office-based vergence/accommodative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Office-based vergence/accommodative therapy
Study: 29352425
Drug: Nanocurcumin (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nanocurcumin (80 mg daily)
Study: 27496096
Drug: Combined intervention
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined intervention (TB medical treatment plus individualized counseling sessions of quitting behavioral therapy plus medical treatment with slow release bupropion)
Study: 27496096
Drug: Brief advice
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brief advice (TB medical treatment plus individualized counseling sessions of quitting behavioral therapy)
Study: 27496096
Drug: Control (just
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (just TB medical treatment)
Study: 21885174
Drug: Paricalcitol, 1
Normalized name: Paricalcitol, 1 mcg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paricalcitol, 1 or 2 μg/d for 16 weeks
Study: 21885174
Drug: Ergocalciferol, 50,000
Normalized name: Ergocalciferol, 50,000 intl units oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ergocalciferol, 50,000 units titrated to achieve serum levels ≥30 ng/mL for 16 weeks
Study: 14711888
Drug: 2 mL
Normalized name: ethanol 2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mL glucose 30%
Study: 14711888
Drug: 0.4 mL
Normalized name: ethanol 0.4 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mL glucose 30%
Study: 14711888
Drug: 2 mL
Normalized name: ethanol 2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mL water (control)
Study: 11376913
Drug: Hypertonic saline
Normalized name: ENTSOL Hypertonic Saline Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertonic saline infusion into the masseter muscle
Study: 11376913
Drug: Hypertonic saline
Normalized name: ENTSOL Hypertonic Saline Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertonic saline infusion into the anterior tibialis muscle
Study: 9246149
Drug: ondansetron 8
Normalized name: ondansetron 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ondansetron 8 mg BID
Study: 9246149
Drug: ondansetron 8
Normalized name: ondansetron 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ondansetron 8 mg TID
Study: 8432921
Drug: Intradermal injections
Normalized name: Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal injections of allergen-antibody complexes
Study: 3109461
Drug: Intravenous mesna
Normalized name: Mesna
DrugBank: Coenzyme M (DB09110)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous mesna (800 mg)
Study: 3109461
Drug: Oral mesna
Normalized name: Mesna
DrugBank: Coenzyme M (DB09110)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral mesna (800 mg)
Study: 29800034
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human pentraxin 2 (10 mg/kg intravenous every 4 weeks, n=77)
Study: 24166586
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg Adefovir plus 100 mg Lamivudine (combination therapy)
Study: 24166586
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg Adefovir (monotherapy)
Study: 20661939
Drug: 10‐g Semmes‐Weinstein
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10‐g Semmes‐Weinstein monofilament and 128‐Hz tuning fork examinations
Study: 16617567
Drug: Dose-intensified chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-intensified chemotherapy
Study: 9570681
Drug: Standard-dose therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose therapy
Study: 3717101
Drug: Sustained-release terbutaline
Normalized name: terbutaline Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release terbutaline sulfate, 5 mg twice daily
Study: 3717101
Drug: Sustained-release terbutaline
Normalized name: terbutaline Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release terbutaline sulfate, 7.5 mg twice daily
Study: 3717101
Drug: Sustained-release theophylline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release theophylline (doses adjusted to achieve serum concentrations of 10 to 20 mg/L)
Study: 23273853
Drug: Neurodevelopmental therapy-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neurodevelopmental therapy-based exercise therapy (Control group).
Study: 20814967
Drug: Intravenous zoledronic
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous zoledronic acid 5 mg plus daily subcutaneous teriparatide 20 µg
Study: 20814967
Drug: Subcutaneous teriparatide
Normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subcutaneous teriparatide 20 µg
Study: 18281442
Drug: Deferasirox (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferasirox (20 mg/kg) administered before a high-fat or standard breakfast
Study: 18281442
Drug: Deferasirox (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferasirox (20 mg/kg) administered concurrently with a standard breakfast
Study: 18281442
Drug: Deferasirox (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferasirox (20 mg/kg) administered under fasted conditions
Study: 18281442
Drug: Deferasirox (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferasirox (20 mg/kg) administered at least 30 minutes before a meal
Study: 18281442
Drug: Deferasirox (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferasirox (20 mg/kg) administered consistently at the same time before meals
Study: 16476694
Drug: AZD6140 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD6140 100 mg bid
Study: 16476694
Drug: AZD6140 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD6140 200 mg bid
Study: 16476694
Drug: AZD6140 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD6140 50 mg bid
Study: 14601905
Drug: Chemotherapy followed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chemotherapy followed by surgery
Study: 30572339
Drug: 500-mg Salvia
Normalized name: SALVIA OFFICINALIS
DrugBank: Sage (DB10982)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500-mg Salvia officinalis capsules once a day for 2 consecutive months
Study: 29357859
Drug: IDN 5933
Normalized name: IDN-7314
DrugBank: IDN-7314 (DB18073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IDN 5933 (Ginkgoselect®Plus) 120 mg twice daily for 6 months
Study: 27089068
Drug: Sequential monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential monotherapy (strategy 1)
Study: 27089068
Drug: Step-up combination
Normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Step-up combination therapy (strategy 2)
Study: 27089068
Drug: Initial combination
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial combination therapy with prednisone (strategy 3)
Study: 27089068
Drug: Initial combination
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial combination therapy with infliximab (strategy 4)
Study: 24891067
Drug: Prucalopride 4
Normalized name: PRUCALOPRIDE
DrugBank: Prucalopride (DB06480)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Prucalopride 4 mg per day for 6 days
Study: 22340631
Drug: Cetuximab (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetuximab (250 mg/m2 I.V. on days 1, 8, and 15) + Mitoxantrone (12 mg/m2 I.V. on day 1) + Prednisone (10 mg daily)
Study: 22340631
Drug: Mitoxantrone (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitoxantrone (12 mg/m2 I.V. on day 1) + Prednisone (10 mg daily)
Study: 16026370
Drug: Continuous subcutaneous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous subcutaneous infusion pump (CSII)
Study: 12447952
Drug: Cefepime or
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefepime or carbapenem monotherapy
Study: 12447952
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of cefepime and aminoglycoside
Study: 8523940
Drug: 500 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 micrograms of inhaled terbutaline for two consecutive days
Study: 8523940
Drug: 500 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 micrograms of inhaled terbutaline
Study: 1936483
Drug: Metformin +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin + SU
Study: 1936483
Drug: Insulin +
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin + SU
Study: 7013087
Drug: Amitriptyline alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline alone or in combination with fluphenazine hydrochloride
Study: 31544375
Drug: Ultrasound-guided acupoint
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided acupoint electrical stimulation therapy (30 min, 3 times a day for 7 days)
Study: 24156189
Drug: Music Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music Therapy with Emotional‐Approach Coping (MT/EAC)
Study: 22368863
Drug: Ginsenoside Rb1
Normalized name: Ginsenoside Rb1
DrugBank: Ginsenoside Rb1 (DB06749)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginsenoside Rb1 (10 mg x kg(‐1) administered intraperitoneally once a day)
Study: 22368863
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (saline 10 mL x kg(‐1) administered intraperitoneally once a day)
Study: 22368863
Drug: Model group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Model group (saline 10 mL x kg(‐1) administered intraperitoneally once a day)
Study: 19702487
Drug: d‐MPH XR
Approvals — FDA: no, EMA: no, PMDA: no
Description: d‐MPH XR 10 mg o.d.
Study: 19702487
Drug: d‐MPH XR
Approvals — FDA: no, EMA: no, PMDA: no
Description: d‐MPH XR 20 mg o.d.
Study: 19702487
Drug: d‐MPH XR
Approvals — FDA: no, EMA: no, PMDA: no
Description: d‐MPH XR 30 mg o.d.
Study: 30700274
Drug: Quadrivalent vaccine
Normalized name: PAPILLOMAVIRUS HUMAN QUADRIVALENT VACCINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadrivalent vaccine
Study: 15510233
Drug: Budenofalk 9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budenofalk 9 mg once daily (o.d.)
Study: 15510233
Drug: Budenofalk 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budenofalk 3 mg three times a day (t.i.d.)
Study: 1618070
Drug: Cisapride (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride (10 mg)
Study: 3126348
Drug: Intravenous recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous recombinant human tissue-type plasminogen activator (rt-PA) 0.75 mg/kg over 90 min
Study: 3126348
Drug: Intravenous streptokinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous streptokinase 1,500,000 IU over 60 min
Study: 29180023
Drug: Patiromer (8.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patiromer (8.4 g/d or 16.8 g/d for 4 weeks)
Study: 21982351
Drug: Formulations with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulations with 1.0% and 5.0% panthenol
Study: 21982351
Drug: Formulations with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulations with panthenol after skin washing with sodium laureth sulphate (SLES)
Study: 12873431
Drug: L-[1-13C] phenylalanine
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-[1-13C] phenylalanine breath test (PBT)
Study: 1855327
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline solution (SS)
Study: 6681030
Drug: Three-monthly assessments
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-monthly assessments
Study: 24571702
Drug: Stabilised stannous
Normalized name: Stannous chloride
DrugBank: Stannous chloride (DB11056)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stabilised stannous (Sn)-containing NaF dentifrice (Oral B/blend-a-Med Pro-Expert)
Study: 22101220
Drug: Early childhood
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early childhood obesity intervention (no specific dosage or duration mentioned)
Study: 16192762
Drug: Ropivacaine with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine with epinephrine (5 mug/ml)
Study: 14515631
Drug: Non-submerged loaded
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-submerged loaded (NSL) implants
Study: 14515631
Drug: Non-submerged non-loaded
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-submerged non-loaded (NSNL) implants
Study: 14515631
Drug: Submerged (S)
Normalized name: S-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Submerged (S) implants
Study: 3890461
Drug: Topical 1.0%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 1.0% indomethacin (5-drop loading dose, applied pre-operatively and post-operatively every 3 hours)
Study: 29931588
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT) combined with functional exercise program (n=11)
Study: 23279452
Drug: Lumbar interlaminar
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lumbar interlaminar injections containing a local anesthetic (lidocaine 0.5%, 6 mL)
Study: 23279452
Drug: Lumbar interlaminar
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lumbar interlaminar epidural injections of 0.5% lidocaine, 5 mL, mixed with 1 mL of non‐particulate betamethasone
Study: 20167441
Drug: Standard antiviral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard antiviral HCV therapy with pegylated interferon and ribavirin
Study: 24169031
Drug: Beauty treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beauty treatments during hospitalization
Study: 24169031
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no beauty treatments)
Study: 1378137
Drug: Carvedilol (12.5-50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol (12.5-50 mg b.i.d. for 4-8 weeks)
Study: 3000138
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg ACTH 4-9 analogue (Org 2766)
Study: 18670743
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (lentinan, RFA, and TACE)
Study: 31848169
Drug: Belimumab administered
Normalized name: Belimumab
DrugBank: Belimumab (DB08879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Belimumab administered 4 to 8 weeks after the first rituximab infusion for 52 weeks
Study: 31848169
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered 4 to 8 weeks after the first rituximab infusion for 52 weeks
Study: 26040429
Drug: Pramlintide 6
Normalized name: PRAMLINTIDE 600MCG/ML SOLN INJ 5ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pramlintide 6 mcg/unit insulin
Study: 26040429
Drug: Pramlintide 9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pramlintide 9 mcg/unit insulin
Study: 26040429
Drug: Pramlintide 12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pramlintide 12 mcg/unit insulin
Study: 24375222
Drug: 16 mL
Normalized name: 16 ML Mvasi 25 MG/ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 mL of 0.1285% ropivacaine
Study: 15080229
Drug: Functional Electrical
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Functional Electrical Therapy (FET)
Study: 17341866
Drug: Topically applied
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topically applied indigo naturalis ointment
Study: 12505248
Drug: Active hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Active hormone replacement therapy (conjugated estrogens for women who had had a hysterectomy or conjugated estrogens with medroxyprogesterone for women with intact uteri)
Study: 12505248
Drug: Placebo for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for hormone replacement therapy
Study: 9869222
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (surgery and radiotherapy)
Study: 773493
Drug: Bran tablets
Normalized name: bran
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bran tablets
Study: 17439510
Drug: Esomeprazole 40
Normalized name: esomeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 40 mg daily for 1 week, followed by 3 weeks of esomeprazole 40 mg daily
Study: 11288947
Drug: Thromboprophylactic agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thromboprophylactic agents (specific agents not mentioned)
Study: 11288947
Drug: New pharmacologic
Approvals — FDA: no, EMA: no, PMDA: no
Description: New pharmacologic agent (specific agent not mentioned)
Study: 3358924
Drug: Meat protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meat protein (60 g)
Study: 28511917
Drug: Oral hypertonic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral hypertonic saline (Ior)
Study: 28511917
Drug: Intravenous hypertonic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous hypertonic saline (Iiv)
Study: 28511917
Drug: Oral hypertonic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral hypertonic saline (IIor)
Study: 28511917
Drug: Intravenous hypertonic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous hypertonic saline (IIiv)
Study: 23650412
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with concurrent trastuzumab (arm C)